Ronald Lee Tuttle

US Patent:

52862526, Feb 15, 1994

Filed:

Dec 11, 1990

Appl. No.:

7/625362

Inventors:

Ronald R. Tuttle - Escondido CA
Clinton E. Browne - Oceanside CA

Assignee:

Gensia Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.

US Patent:

57600015, Jun 2, 1998

Filed:

May 22, 1995

Appl. No.:

8/447143

Inventors:

Beverly E. Girten - San Diego CA
Richard A. Houghten - Del Mar CA
Costas C. Loullis - Cardiff CA
Mark J. Suto - San Deigo CA
Ronald R. Tuttle - Escondido CA

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 16

Abstract:

The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.

US Patent:

51083639, Apr 28, 1992

Filed:

Feb 9, 1989

Appl. No.:

7/308683

Inventors:

Ronald R. Tuttle - Escondido CA
Clinton E. Browne - Oceanside CA

Assignee:

Gensia Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.

US Patent:

52344045, Aug 10, 1993

Filed:

Oct 11, 1991

Appl. No.:

7/775735

Inventors:

Ronald R. Tuttle - Escondido CA
Clinton E. Browne - Oceanside CA

Assignee:

Gensia Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61N 130

US Classification:

604 20

Abstract:

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute and adaptive cardiovascular responses similar to those elicited by aerobic activity are provided. The acute responses to the exercise simulating agent are used to diagnose and evaluate CAD in lieu of the acute responses to aerobic exercise. Due to their adaptive responses these compounds may be used to treat CAD in lieu of the adaptive responses caused by aerobic exercise training or to treat other conditions where the adaptive responses caused by aerobic exercise are desirable.

US Patent:

57417741, Apr 21, 1998

Filed:

Sep 27, 1996

Appl. No.:

8/722279

Inventors:

Beverly E. Girten - San Diego CA
Ronald R. Tuttle - Escondido CA

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800
C07K 500
C07K 700
C07K 1700

US Classification:

514 8

Abstract:

The present invention relates to the use of a cytokine regulatory agent to reduce the severity of rheumatoid arthritis.

US Patent:

57261563, Mar 10, 1998

Filed:

Sep 12, 1995

Appl. No.:

8/527056

Inventors:

Beverly E. Girten - San Diego CA
Ali Andalibi - San Diego CA
Amaresh Basu - San Diego CA
Patrick Fagan - Escondido CA
Richard A. Houghten - Del Mar CA
Costas C. Loullis - Cardiff CA
Paul Omholt - San Diego CA
Ronald R. Tuttle - Escondido CA
Mark J. Suto - San Diego CA
Patricia A. Weber - Stevensville MT

Assignee:

Trega Biosciences, Inc. - San Diego CA

International Classification:

A61K 3800

US Classification:

514 16

Abstract:

The present invention relates to novel peptides that are potent cytokine regulatory agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine regulatory agent. Administration of such a cytokine regulatory agent to a subject can enhance or restrain cytokine activity. Thus, the present invention provides a method of regulating cytokine activity in a subject having a condition characterized by aberrant or altered cytokine activity. The invention also provides methods of treating such conditions, including, for example, disuse deconditioning, diseases mediated by nitric oxide and cytokines, adverse drug reactions, obesity, septic shock, and adverse side effects due to cancer chemotherapy or occurring as in response to organ transplantation.

US Patent:

56588895, Aug 19, 1997

Filed:

Dec 14, 1994

Appl. No.:

8/355836

Inventors:

Harry E. Gruber - San Diego CA
Ronald R. Tuttle - Escondido CA
Clinton E. Browne - Oceanside CA
Jack W. Reich - Carlsbad CA
Ernest K. Metzner - Del Mar CA
Paul J. Marangos - Encinitas CA

Assignee:

Gensia Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 3170

US Classification:

514 43

Abstract:

AICA riboside and prodrugs of AICA riboside are provided which lower blood glucose for the treatment of various pathologic conditions, including hypoglycemia, insulin deficiency, insulin resistance diabetes and Syndrome X. Prodrugs of AICA riboside provide AICA riboside in an orally bioavailable form. The use of adenosine kinase inhibition and ZMP enhancement for lowering blood glucose are also described.

US Patent:

55978436, Jan 28, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/485609

Inventors:

Beverly E. Girten - San Diego CA
Ronald R. Tuttle - Escondido CA

Assignee:

Houghten Pharmaceuticals - San Diego CA

International Classification:

A61K 3142
A61K 3136

US Classification:

514376

Abstract:

The present invention provides a method of reducing a wasting condition, which can occur due to a pathology or to a particular physiologic or metabolic state in a subject, by administering to the subject a substituted 1,3-benzodioxole.